The FNIH Biomarkers Consortium: Past Accomplishments and New Strategic Direction.

Other

Abstract

The FNIH Biomarkers Consortium (BC) is a public-private partnership that aims to facilitate drug development with biomarkers across a range of therapeutic areas. The BC is organized to address specific precompetitive biomarker projects, giving participating stakeholders a role in the design and conduct of projects, and making the results freely public. Ultimately, the goals of the BC are to accelerate the development of new medicines, inform regulatory decision-making, and improve patient care. Here, we describe how the BC works and briefly highlight its accomplishments. The BC has had many notable successful biomarker projects in the past 12 years, including I-SPY2, which has improved clinical trials and biomarker use for breast cancer, and an evidentiary framework for biomarker qualification. Recently, the BC has undergone a strategic expansion of its scope to include related drug development tools along the lines of the BEST (Biomarkers, EndpointS, and other Tools) resource. This article is protected by copyright. All rights reserved.

Authors

Menetski, Joseph P; Hoffmann, Steven; Cush, Stephanie; Kamphaus, Tania Nayak; Austin, Christopher; Herrling, Paul; Wagner, John A;

External Links